Microcap Research·Est. 2026
TSXV: AVCR · Healthcare / Point-of-Care Diagnostics (Pharmacy Technology)

Avricore Health Inc.

Microcap Research rates Avricore Health Inc. (TSXV: AVCR) Spec. Buy with a 12-month price target of C$0.11, about 120% above the C$0.05 share price at publication on Jun 11, 2026. Market capitalisation at publication: C$5.1M.

Latest Rating
Spec. Buy
12-mo Target
C$0.11
Price at Publication
C$0.05
Implied Upside
120%
Market Cap
C$5.1M

Coverage history 01 report

01
Avricore Health AVCR-2026-06 Current
A deliberate, high-stakes pivot: Avricore walked away from the Shoppers Drug Mart contract (~97% of revenue) to bet entirely on the UK NHS pharmacy market, collapsing revenue ~90% and triggering going-concern doubt. At a ~C$5M market cap with ~700 analyzers staged, blue-chip NHS partners, and a September 2026 national independent-prescriber rollout, the stock is a cheap option on UK execution — with first subscription revenue expected H2 2026.
Healthcare / Point-of-Care Diagnostics (Pharmacy Technology)
Spec. Buy
120%

Avricore Health Inc. (AVCR) — key questions

What is Microcap Research's current rating on Avricore Health Inc. (AVCR)?

Microcap Research rates Avricore Health Inc. (TSXV: AVCR) Spec. Buy with a 12-month price target of C$0.11, about 120% above the C$0.05 share price at publication on Jun 11, 2026. Market capitalisation at publication: C$5.1M. This is the current call, published in the most recent of 1 Microcap Research report on the company.

How many reports has Microcap Research published on Avricore Health Inc. (AVCR)?

1 report, beginning in 2026. The most recent is dated Jun 11, 2026; there are no earlier reports.

Has Microcap Research's rating on Avricore Health Inc. (AVCR) changed?

Microcap Research initiated coverage of Avricore Health Inc. (AVCR) on Jun 11, 2026 at Spec. Buy, with a C$0.11 price target. That is still the current call; it has not been revised.

What does Avricore Health Inc. (AVCR) do?

Avricore Health Inc. is a Healthcare / Point-of-Care Diagnostics (Pharmacy Technology) company listed on the TSXV as TSXV: AVCR. Avricore Health (formerly Vanc Pharmaceuticals; renamed in 2018) is incorporated in British Columbia and trades on the TSX Venture Exchange under AVCR and on the OTCQB as AVCRF. Its sole operating asset is HealthTab™, held through UK subsidiary HealthTab Ltd. The platform is a complete, turnkey POCT solution combining instruments, cloud software, standardized workflows…

What are the main risks Microcap Research flags on Avricore Health Inc. (AVCR)?

As of the Jun 11, 2026 report — Going Concern / Liquidity (HIGH); No Proven UK Revenue (HIGH); Execution / Single-Market Concentration (MEDIUM); Dilution / Warrant Overhang (MEDIUM); Microcap Liquidity (MEDIUM); Customer Concentration (MEDIUM)